Conditions

This post was originally published on this site Treatment with Checkpoint Therapeutics’ investigational immunotherapy Cosibelimab supports a positive anti-cancer response in approximately 28% of patients with advanced solid tumors, interim results from an ongoing Phase 1 trial show. In particular, the therapy showed greater potential to treat those with non-small-cell lung carcinoma and cutaneous squamous cell…

This post was originally published on this site Lymphoma cells can become resistant to therapy as they acquire novel genetic mutations, but a new study has found that they can also become resistant as they reprogram which genes are turned “on” or “off.” This particular resistance mechanism was seen in B-cell lymphomas in response to…

This post was originally published on this site A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang Bio’s investigational autologous (patient-derived) CS1-chimeric antigen receptor (CAR) T-cell therapy. The trial (NCT03710421), designed to assess the therapy’s safety and tolerability, is being conducted at the City of Hope…

This post was originally published on this site Researchers at Michigan State University (MSU) were granted $50,000 to investigate why only a fraction of ovarian cancer patients respond to treatment with PARP inhibitors.  The grant, awarded by the Michigan Ovarian Cancer Alliance, will allow the team to better understand the biological mechanisms underlying patients’ response…

This post was originally published on this site Men whose tumors contain mutations in the retinoblastoma (RB1) gene have higher risks of prostate cancer relapse and mortality while receiving first-line conventional anti-cancer therapies, a study says. According to researchers, genetic screenings aimed at identifying patients whose tumors may contain such genetic alterations may be crucial…

This post was originally published on this site Breast cancer patients in the U.S. who are receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), and have mutated PIK3CA can now be treated with Novartis‘ Piqray (alpelisib) in combination with Faslodex (fulvestrant). The U.S. Food and Drug Administration (FDA) has approved the use of this…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted Cue Biopharma‘s investigational new drug (IND) application for its immunotherapy candidate CUE-101, clearing the way for the first-in-human Phase 1 trial in people with head and neck squamous cell carcinoma (HNSCC) caused by human papillomavirus (HPV). CUE-101 is…

This post was originally published on this site Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual health, a survey…

This post was originally published on this site Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening in patients with multiple myeloma who have failed prior treatments, including Revlimid (lenalidomide), results from a pivotal clinical trial show. Building on this data, the European Commission recently approved the triple combo as an early…

This post was originally published on this site DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 Phase 2 trial show. Interim data announced by DPX-Survivac‘s developer, IMV, revealed that all 15 patients with smaller tumors…